A study to evaluate blood levels of a hormone released from the heart (NT-pro-BNP) for determining need for closure of a blood vessel (Patent Ductus Arteriosus) in premature newborns.
Not Applicable
- Conditions
- Health Condition 1: P073- Preterm [premature] newborn [other]
- Registration Number
- CTRI/2022/12/048305
- Lead Sponsor
- Vishal Vishnu Tewari
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All preterm neonates <= 31 weeks period of gestation serially admitted to the NICU of Command hospital (WC), Chandimandir will be included in the study.
Exclusion Criteria
Neonates with major congenital malformations, symmetric Intrauterine growth restriction, any congenital heart diseases, gestation < 24 weeks or >=32 weeks
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess NT-pro-BNP for identifying preterm neonates at â?¤ 31 weeks gestation at risk for developing symptomatic patent ductus arteriosus necessitating pharmacologic closureTimepoint: To assess NT-pro-BNP for identifying preterm neonates at â?¤ 31 weeks gestation at risk for developing symptomatic patent ductus arteriosus necessitating pharmacologic closure
- Secondary Outcome Measures
Name Time Method 1.Correlate NT-pro-BNP levels with echocardiography markers of hemodynamically significant PDA (hs-PDA) <br/ ><br>2.Compare NT-pro-BNP levels in preterm neonates with symptomatic PDA who underwent pharmacologic closure with those who had spontaneous closure of PDA <br/ ><br>3.Incidence of mortality, bronchopulmonary dysplasia (BPD), intraventricular hemorrhage (IVH) and retinopathy of prematurity (ROP) <br/ ><br>Timepoint: By day of discharge from the hospital